Closely observe for at least 15 min following vaccination in case of anaphylactic event. Postpone vaccination in individuals suffering from acute severe febrile illness. Do not administer intravascularly or intradermally. No available data on SC administration. Caution in individuals w/ thrombocytopenia or any coagulation disorder following IM administration. Safety & immunogenicity data are not available for immunocompromised individuals. Patients receiving immunosuppressive treatment or those w/ immunodeficiency may have reduced immune response to Arexvy. Need for revaccination w/ a subsequent dose has not been established. Minor influence on ability to drive & use machines. Not recommended during pregnancy & in breast-feeding/lactating women. Safety & efficacy in childn have not been established.
May be administered concomitantly w/ seasonal flu vaccine (quadrivalent, standard dose, unadjuvanted, inactivated). No data on co-administration w/ high-dose or adjuvanted seasonal flu vaccines. Always administer at different inj sites if to be given at the same time as another injectable vaccine. Concomitant administration w/ other vaccines has not been studied.
J07BX05 - respiratory syncytial virus vaccines ; Belongs to the class of other viral vaccines. Used for active immunization against respiratory syncytial virus.
Sign Out
2445675f-e015-4a1a-90fc-b1620092e188.GIF)
